Seeking Alpha

Myriad Genetics (MYGN -2.9%) shares slide after the U.S. Supreme Court agreed to hear a...

Myriad Genetics (MYGN -2.9%) shares slide after the U.S. Supreme Court agreed to hear a challenge to the practice of issuing patents on human genes. Goldman Sachs cuts shares to Neutral from Buy on concerns that a final decision likely won't be reached before midyear. But Jefferies maintains its Buy rating, believing MYGN's patents should ultimately be upheld.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector